Premium
Revelation ® Tx Microcatheter Maze Procedure Successfully Treats Paroxysmal AF
Author(s) -
Kocheril A.
Publication year - 2003
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1046/j.1460-9592.2003.t01-2-00231_6.x
Subject(s) - medicine , paroxysmal atrial fibrillation , refractory (planetary science) , ablation , sinus rhythm , atrial fibrillation , prospective cohort study , cardiology , surgery , anesthesia , physics , astrobiology
Currently the recommended treatment for atrial fibrillation is pharmacologic therapy. The ability of antiarrhythmic drugs to maintain normal sinus rhythm ranges from 39% to 79% in the first year. A multicenter, prospective clinical study involving 20 centers and 80 subjects has shown promising results for an effective, minimally invasive treatment of paroxysmal AF with a novel RF ablation microcatheter (Cardima ® ). Methods: Patients with drug refractory, paroxysmal AF were treated with an RF ablation version of the MAZE procedure placing linear lesions in the right atrium. Patients served as their own controls, establishing a baseline episode frequency in the 30 days prior to treatment. Treatment outcomes were compared to baseline to determine treatment effectiveness. Results: Of 79 subjects who reached 6 months follow up by July 2002, 46.8% reported 100% reduction in symptomatic AF episodes and 84.8% reported ≥50% reduction in episode frequency. Subjects also demonstrated clinically significant and statistically significant improvements in quality of life measurements. Conclusion: These results indicate substantial patient benefit from the minimally invasive maze procedure performed with the REVELATION Tx Microcatheter.